Cinobufacini Injection Improves the Efficacy of Chemotherapy on Advanced Stage Gastric Cancer: A Systemic Review and Meta-Analysis

Table 2

Meta-analysis of KPS, side-effects and tumor-related pain.

Meta-analysis	No. of study	Risk Ratio [%95 CI]				heterogeneity
		Fix-model	P value	Random-model	P value	I^2(%)	P value
KPS	6	1.83 [1.40, 2.39]	P < 0.00001	1.76 [1.35, 2.29]	P < 0.0001	0	0.46
leukocytopenia	6	0.78 [0.65, 0.93]	P = 0.007	0.76 [0.58, 0.99]	P = 0.04	50	0.07
Grades III-IV leukocytopenia	4	0.61 [0.33, 1.14]	P = 0.12	0.58 [0.23, 1.46]	P = 0.25	20	0.29
nausea and vomiting	5	0.68 [0.53, 0.86]	P = 0.001	0.68 [0.48, 0.96]	P = 0.03	47	0.11
Grades III-IV nausea and vomiting	4	0.34 [0.14, 0.82]	P = 0.02	0.44 [0.17, 1.13]	P = 0.09	4	0.37
hand-foot syndrome	3	0.55 [0.33, 0.91]	P = 0.02	0.54 [0.32, 0.91]	P = 0.02	0	0.48
tumor-related pain	2	1.81 [1.30, 2.54]	P = 0.0005	1.83 [1.31, 2.55]	P = 0.0004	0	0.73
anemia	3	0.79 [0.58, 1.08]	P = 0.14	0.80 [0.59, 1.09]	P = 0.15	0	0.83
diarrhea	5	0.77 [0.52, 1.15]	P = 0.21	0.76 [0.51, 1.14]	P = 0.19	0	0.8
peripheral neurotoxicity	3	0.64 [0.52, 0.80]	P < 0.0001	0.57 [0.23, 1.43]	P = 0.23	91	<0.00001
oral mucositis	2	0.46 [0.25, 0.83]	P = 0.01	0.37 [0.04, 3.47]	P = 0.39	88	0.004